{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:07:01Z","timestamp":1762542421754,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM103464"],"award-info":[{"award-number":["P20GM103464"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.nmd.2015.05.008","type":"journal-article","created":{"date-parts":[[2015,5,26]],"date-time":"2015-05-26T22:27:37Z","timestamp":1432679257000},"page":"699-705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The effect of the DcpS inhibitor D156844 on the protective action of follistatin in mice with spinal muscular atrophy"],"prefix":"10.1016","volume":"25","author":[{"given":"Ashlee W.","family":"Harris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2912-6400","authenticated-orcid":false,"given":"Matthew E.R.","family":"Butchbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2015.05.008_bib0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/nbdi.1996.0010","article-title":"The neurobiology of childhood spinal muscular atrophy","volume":"3","author":"Crawford","year":"1996","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.nmd.2015.05.008_bib0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.nmd.2015.05.008_bib0020","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nmd.2015.05.008_bib0025","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2015.05.008_bib0030","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/hmg\/6.8.1205","article-title":"The survival motor neuron protein in spinal muscular atrophy","volume":"6","author":"Coovert","year":"1997","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2015.05.008_bib0035","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng0797-265","article-title":"Correlation between severity and SMN protein level in spinal muscular atrophy","volume":"16","author":"Lefebvre","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.nmd.2015.05.008_bib0040","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1086\/515465","article-title":"Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number","volume":"60","author":"McAndrew","year":"1997","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nmd.2015.05.008_bib0045","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/hmg\/9.3.333","article-title":"The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn-\/- mice and results in a mouse with spinal muscular atrophy","volume":"9","author":"Monani","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2015.05.008_bib0050","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/71709","article-title":"A mouse model for spinal muscular atrophy","volume":"24","author":"Hsieh-Li","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.nmd.2015.05.008_bib0055","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.nbd.2010.01.006","article-title":"Neuromuscular defects and breathing disorders in a new mouse model of spinal muscular atrophy","volume":"38","author":"Michaud","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.nmd.2015.05.008_bib0060","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/adt.2014.587","article-title":"Assays for the identification and prioritization of drug candidates for spinal muscular atrophy","volume":"12","author":"Cherry","year":"2014","journal-title":"Assay Drug Dev Technol"},{"key":"10.1016\/j.nmd.2015.05.008_bib0065","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1093\/hmg\/ddi205","article-title":"Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy","volume":"14","author":"Jarecki","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2015.05.008_bib0070","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1021\/jm061475p","article-title":"Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy","volume":"51","author":"Thurmond","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.nmd.2015.05.008_bib0075","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/hmg\/ddp510","article-title":"Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy","volume":"19","author":"Butchbach","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2015.05.008_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2014.03.005","article-title":"The effect of diet on the protective action of D156844 observed in spinal muscular atrophy mice","volume":"256","author":"Butchbach","year":"2014","journal-title":"Exp Neurol"},{"key":"10.1016\/j.nmd.2015.05.008_bib0085","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1093\/hmg\/ddt257","article-title":"The DcpS inhibitor RG3039 improves motor function in SMA mice","volume":"22","author":"Van Meerbeke","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2015.05.008_bib0090","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1093\/hmg\/ddt258","article-title":"The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models","volume":"22","author":"Gogliotti","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2015.05.008_bib0095","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1021\/cb800120t","article-title":"DcpS as a therapeutic target for spinal muscular atrophy","volume":"3","author":"Singh","year":"2008","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.nmd.2015.05.008_bib0100","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/hmg\/ddn426","article-title":"Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy","volume":"18","author":"Rose","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2015.05.008_bib0105","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/hmg\/ddi078","article-title":"SMN\u03947, the major product of the centromeric survival motor neuron gene (SMN2), extends survival in mice with spinal muscular atrophy and associates with full-length SMN","volume":"14","author":"Le","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2015.05.008_bib0110","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.bbrc.2009.11.148","article-title":"Effect of diet on the survival and phenotype of a mouse model for spinal muscular atrophy","volume":"391","author":"Butchbach","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.nmd.2015.05.008_bib0115","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jneumeth.2006.11.002","article-title":"A novel method for oral delivery of compounds to the neonatal SMN\u03947 model of spinal muscular atrophy","volume":"161","author":"Butchbach","year":"2007","journal-title":"J Neurosci Methods"},{"key":"10.1016\/j.nmd.2015.05.008_bib0120","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.nbd.2007.04.009","article-title":"Abnormal motor phenotype in the SMN\u03947 mouse model of spinal muscular atrophy","volume":"27","author":"Butchbach","year":"2007","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.nmd.2015.05.008_bib0125","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1093\/hmg\/ddp253","article-title":"Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice","volume":"18","author":"Sumner","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2015.05.008_bib0130","doi-asserted-by":"crossref","first-page":"9306","DOI":"10.1073\/pnas.151270098","article-title":"Regulation of myostatin activity and muscle growth","volume":"98","author":"Lee","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nmd.2015.05.008_bib0135","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/mus.21244","article-title":"Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease","volume":"39","author":"Rodino-Klapac","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2015.05.008_bib0140","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.nmd.2011.10.012","article-title":"Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of spinal muscular atrophy","volume":"22","author":"Rindt","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2015.05.008_bib0145","doi-asserted-by":"crossref","first-page":"e789","DOI":"10.1371\/journal.pone.0000789","article-title":"Quadrupling muscle mass in mice by targeting TGF-\u03b2 signaling pathways","volume":"8","author":"Lee","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2015.05.008_bib0150","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/emmm.201202305","article-title":"Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds","volume":"5","author":"Cherry","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.nmd.2015.05.008_bib0155","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1126\/science.1250127","article-title":"SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy","volume":"345","author":"Naryshkin","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.nmd.2015.05.008_bib0160","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/hmg\/ddp030","article-title":"Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function of SMA mice in vivo","volume":"18","author":"Heier","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2015.05.008_bib0165","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/hmg\/ddp333","article-title":"Delivery of a read-through inducing compound, TC007, lessens the severity of a SMA animal model","volume":"18","author":"Mattis","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2015.05.008_bib0170","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1471-2202-10-142","article-title":"Subcutaneous administration of TC007 reduces disease severity in an animal model of SMA","volume":"10","author":"Mattis","year":"2009","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.nmd.2015.05.008_bib0175","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neulet.2012.07.024","article-title":"Analysis of a read-through promoting compound in a severe mouse model of spinal muscular atrophy","volume":"525","author":"Mattis","year":"2012","journal-title":"Neurosci Lett"},{"year":"2004","series-title":"Protective effects of butyrate analogues and prodrugs on a mouse model for spinal muscular atrophy","author":"Butchbach","key":"10.1016\/j.nmd.2015.05.008_bib0180"},{"year":"2005","series-title":"SMN-independent amelioration of mouse spinal muscular atrophy by butyrate prodrugs","author":"Butchbach","key":"10.1016\/j.nmd.2015.05.008_bib0185"},{"key":"10.1016\/j.nmd.2015.05.008_bib0190","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/hmg\/ddq021","article-title":"Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model","volume":"19","author":"Bowerman","year":"2010","journal-title":"Hum Mol Genet"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896615001595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896615001595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:03:10Z","timestamp":1760774590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896615001595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0960896615001595"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2015.05.008","relation":{},"ISSN":["0960-8966"],"issn-type":[{"type":"print","value":"0960-8966"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of the DcpS inhibitor D156844 on the protective action of follistatin in mice with spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2015.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}